Prosecution Insights
Last updated: April 19, 2026
Application No. 17/997,598

NANOSTRUCTURED HYBRID MATERIAL BASED ON NIOBIUM OLIGOMERS, OBTENTION METHOD, AND USE

Non-Final OA §103§112
Filed
Oct 31, 2022
Examiner
HOLLOMAN, NANNETTE
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Odonto Tech Pesquisa E Inovacao Ltda
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
83%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
469 granted / 778 resolved
At TC average
Strong +23% interview lift
Without
With
+22.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
19 currently pending
Career history
797
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
52.6%
+12.6% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
18.2%
-21.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 778 resolved cases

Office Action

§103 §112
DETAILED ACTION DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-3, in the reply filed on 10/02/2025 is acknowledged. Claims 4-9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 10/02/2025. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 2 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 2 recites “dissolving the niobium compounds, containing between 1 and 5 g/L of niobium.” It is not clear how one dissolves a compound that appears to be in solution because of the unit of the concentration given. Therefore the claim is indefinite. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1 and 2 are rejected under 35 U.S.C. 103 as being unpatentable over De Oliveira et al. (BR102019024108, English translation). De Oliveira et al. disclose a nanometric material derived from the reaction of negatively charged niobium oxide with hydrogen peroxide and subsequently methylene blue in a ratio of niobium to quaternary ammonium, i.e. methylene blue ranging between 1:0.5 and 1:2 (paragraphs 14, 16 and 27). In regard to claim 2, De Oliveira et al. disclose the nanostructure material of instant claim 1. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product of the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process. The prior art discloses the use of 1:0.5 and 1:2 of niobium to quaternary ammonium, the prior art differs from the instant claims insofar as it does not disclose the particular endpoints recited therein, i.e. 10 to 2000 mg/L of quaternary ammonium for concentration s between 100 and 3000 mg/L of niobium. It is well-settled, however, that even a slight overlap in range establishes a prima facie case of obviousness. In re Peterson, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003). Accordingly, since an overlap plainly exists here, it would have been obvious to have selected values within the overlap, consistent with the reasoning of the Peterson decision. Claim(s) 3 is rejected under 35 U.S.C. 103 as being unpatentable over De Oliveira et al. (BR102019024108, English translation) in view of Karlinsey (US Patent Pub. 2009/014242). De Oliveira et al. is discussed above and differs from the instant claims insofar as they do not disclose an alcohol gel. Karlinsey discloses bioactive niobium formed in gels which comprise alcohol ([0004] and [0123]). It would have been obvious to one of ordinary skill in to art to have formed the composition of De Oliveira into a gel since it is known to form niobium into gel formulations at taught by Karlinsey. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05. Therefore, it would be obvious to have varied the amount of niobium material within the gel motivated by the desire to achieve the desired effect. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NANNETTE HOLLOMAN whose telephone number is (571)270-5231. The examiner can normally be reached Monday-Friday 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Frederick Krass can be reached at (571)272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NANNETTE HOLLOMAN/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Oct 31, 2022
Application Filed
Dec 16, 2025
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594224
Oral Care Compositions and Methods of Use
2y 5m to grant Granted Apr 07, 2026
Patent 12582588
SOLID COSMETIC COMPOSITION FOR BLOCKING ULTRAVIOLET RADIATION HAVING WATER RESISTANCE AND CLEANSING PROPERTIES
2y 5m to grant Granted Mar 24, 2026
Patent 12582587
SUNSCREEN COMPOSITION AND METHODS OF PROTECTION FROM ULTRAVIOLET AND VISIBLE LIGHT
2y 5m to grant Granted Mar 24, 2026
Patent 12576027
DICLOFENAC TOPICAL FORMULATION WITH A HIGH ABSORPTION RATE
2y 5m to grant Granted Mar 17, 2026
Patent 12576153
PRESERVATIVE SYSTEMS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
83%
With Interview (+22.9%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 778 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month